Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral …

M Hümpel, U Täuber, W Kuhnz, M Pfeffer… - Hormone Research in …, 1990 - karger.com
The study included 69 women taking a desogestrel (n= 30)-or gestodene (n= 39)-containing
low-dose combined oral contraceptive for at least 3 months. Group size was calculated to …

[PDF][PDF] New developments in hormonal therapy for acne

JKL Tan - Skin therapy lett, 2007 - Citeseer
Oral contraceptives (OCs) are a valuable option for the treatment of women with acne. The
use of OCs can be considered across the spectrum of acne disease severity in women. In …

A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 …

J Endrikat, U Müller, B Düsterberg - Contraception, 1997 - Elsevier
The aim of this study was to compare contraceptive reliability, cycle control, and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …

Pharmacokinetics of desogestrel

HD McClamrock, EY Adashi - American journal of obstetrics and …, 1993 - Elsevier
A synthetic form of desogestrel, a gonane progestin, was developed because desogestrel's
enhanced selectivity eliminates adverse, androgen-dependent, metabolic effects at …

Use of oral contraceptives for management of acne vulgaris

JC Harper - Advances in Acne Management, An Issue of …, 2016 - books.google.com
Combination oral contraceptive pills (COCs) are effective at reducing acne in women. COCs
are useful for women with and without clinical and/or laboratory signs of hyperandrogenism …

Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel: pharmacokinetics and pharmacodynamic parameters

C Jung-Hoffmann, M Fitzner, H Kuhl - Hormone Research in Paediatrics, 1991 - karger.com
The serum concentrations of ethinylestradiol (EE) and 3-keto-desogestrel (KDG) were
compared during treatment with a combination of 20 µg EE+ 150 µg DG (20EE/DG) or of 30 …

Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone …

C Campagnoli, P Colombo, D De Aloysio… - Maturitas, 2002 - Elsevier
Objectives: To assess differences in two sequential combined hormone replacement therapy
(HRT) products on selected cardiovascular and breast metabolic markers. The products …

[HTML][HTML] Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex …

GR Kraemer, RR Kraemer, BW Ogden, RE Kilpatrick… - Fertility and sterility, 2003 - Elsevier
OBJECTIVE: To examine the variability of serum estrogens in response to transdermal
estrogen replacement therapy (ET), and to determine the effects on androgens and sex …

Managing cutaneous manifestations of hyperandrogenic disorders: the role of oral contraceptives

I Wiegratz, H Kuhl - Treatments in endocrinology, 2002 - Springer
Cutaneous manifestations of hyperandrogenic disorders (acne, seborrhea, hirsutism and
androgenetic alopecia) can be caused by elevated levels of free testosterone or androgen …

Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents

R Sabatini, G Orsini, R Cagiano, G Loverro - Contraception, 2007 - Elsevier
BACKGROUND: The aim of this study was to assess the noncontraceptive benefits of two
combined oral contraceptives, containing progestins with well-known antiandrogenic …